In the last three months, 6 analysts have published ratings on CME Group (NASDAQ:CME), offering a diverse range of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $316.83, a high estimate of $340.00, and a low estimate of $304.00. This current average has increased by 4.51% from the previous average price target of $303.17.

Decoding Analyst Ratings: A Detailed Look

An in-depth analysis of recent analyst actions unveils how financial experts perceive CME Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into CME Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on CME Group analyst ratings.

About CME Group

Financial Milestones: CME Group's Journey

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Negative Revenue Trend: Examining CME Group's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -2.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.

Net Margin: CME Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 58.31% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): CME Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.21%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): CME Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.49%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: CME Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.